Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.
Rossing P, Anker SD, Filippatos G, Pitt B, Ruilope LM, Birkenfeld AL, McGill JB, Rosas SE, Joseph A, Gebel M, Roberts L, Scheerer MF, Bakris GL, Agarwal R; FIDELIO-DKD and FIGARO-DKD Investigators. Rossing P, et al. Among authors: gebel m. Diabetes Care. 2022 Dec 1;45(12):2991-2998. doi: 10.2337/dc22-0294. Diabetes Care. 2022. PMID: 35972218 Free PMC article. Clinical Trial.
Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone.
Agarwal R, Anker SD, Bakris G, Filippatos G, Pitt B, Rossing P, Ruilope L, Gebel M, Kolkhof P, Nowack C, Joseph A; FIDELIO-DKD and FIGARO-DKD Investigators. Agarwal R, et al. Among authors: gebel m. Nephrol Dial Transplant. 2022 May 25;37(6):1014-1023. doi: 10.1093/ndt/gfaa294. Nephrol Dial Transplant. 2022. PMID: 33280027 Free PMC article.
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.
Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, Kolkhof P, Nowack C, Gebel M, Ruilope LM, Bakris GL; FIDELIO-DKD and FIGARO-DKD investigators. Agarwal R, et al. Among authors: gebel m. Eur Heart J. 2022 Feb 10;43(6):474-484. doi: 10.1093/eurheartj/ehab777. Eur Heart J. 2022. PMID: 35023547 Free PMC article. Clinical Trial.
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis.
Filippatos G, Anker SD, August P, Coats AJS, Januzzi JL, Mankovsky B, Rossing P, Ruilope LM, Pitt B, Sarafidis P, Teerlink JR, Kapelios CJ, Gebel M, Brinker M, Joseph A, Lage A, Bakris G, Agarwal R. Filippatos G, et al. Among authors: gebel m. Eur Heart J Cardiovasc Pharmacother. 2023 Feb 2;9(2):183-191. doi: 10.1093/ehjcvp/pvad001. Eur Heart J Cardiovasc Pharmacother. 2023. PMID: 36639130 Free PMC article.
A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease.
Agarwal R, Pitt B, Palmer BF, Kovesdy CP, Burgess E, Filippatos G, Małyszko J, Ruilope LM, Rossignol P, Rossing P, Pecoits-Filho R, Anker SD, Joseph A, Lawatscheck R, Wilson D, Gebel M, Bakris GL. Agarwal R, et al. Among authors: gebel m. Clin Kidney J. 2022 Oct 30;16(2):293-302. doi: 10.1093/ckj/sfac234. eCollection 2023 Feb. Clin Kidney J. 2022. PMID: 36864892 Free PMC article.
Bleeding Outcomes in Patients Treated With Asundexian in Phase II Trials.
Eikelboom JW, Mundl H, Alexander JH, Caso V, Connolly SJ, Coppolecchia R, Gebel M, Hart RG, Holberg G, Keller L, Patel MR, Piccini JP, Rao SV, Shoamanesh A, Tamm M, Viethen T, Yassen A, Bonaca MP. Eikelboom JW, et al. Among authors: gebel m. J Am Coll Cardiol. 2024 Feb 13;83(6):669-678. doi: 10.1016/j.jacc.2023.12.004. J Am Coll Cardiol. 2024. PMID: 38325992 Clinical Trial.
Real life studies and good clinical practice - Authors' reply.
Ageno W, Mantovani LG, Haas S, Kreutz R, Monje D, Schneider J, van Eickels M, Gebel M, Zell E, Turpie AG. Ageno W, et al. Among authors: gebel m. Lancet Haematol. 2016 Apr;3(4):e160-1. doi: 10.1016/S2352-3026(16)00027-2. Lancet Haematol. 2016. PMID: 27063973 No abstract available.
Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis.
Mantovani LG, Haas S, Kreutz R, Folkerts K, Gebel M, Monje D, Schneider J, van Eickels M, Sahin K, Zell E, Ageno W, Turpie AGG. Mantovani LG, et al. Among authors: gebel m. Eur J Intern Med. 2019 Mar;61:29-33. doi: 10.1016/j.ejim.2018.10.002. Epub 2018 Oct 19. Eur J Intern Med. 2019. PMID: 30342973 Free article.
186 results